Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) was downgraded by Wedbush from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. They currently have a $3.00 price objective on the biotechnology company’s stock, down from their prior price objective of $8.00. Wedbush‘s price objective indicates a potential downside of 16.90% from the company’s current price.
Several other research analysts have also recently weighed in on ACRS. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Canaccord Genuity Group lifted their price objective on Aclaris Therapeutics from $10.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a report on Wednesday, October 28th. Finally, Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Three research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Aclaris Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $10.78.
Check Out Our Latest Stock Report on ACRS
Aclaris Therapeutics Trading Down 7.9%
ACRS stock opened at $3.61 on Tuesday. The firm has a 50 day moving average of $4.38 and a 200-day moving average of $4.53. Aclaris Therapeutics has a 12 month low of $2.34 and a 12 month high of $6.60. The firm has a market capitalization of $572.59 million, a P/E ratio of -6.22 and a beta of 0.96.
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. Aclaris Therapeutics had a negative net margin of 1,244.09% and a negative return on equity of 59.19%. The business had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.27 million. Sell-side analysts predict that Aclaris Therapeutics will post -0.56 EPS for the current year.
Institutional Trading of Aclaris Therapeutics
A number of hedge funds have recently made changes to their positions in ACRS. Bank of New York Mellon Corp increased its stake in Aclaris Therapeutics by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 207,024 shares of the biotechnology company’s stock valued at $776,000 after acquiring an additional 3,507 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Aclaris Therapeutics by 20.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 26,858 shares of the biotechnology company’s stock worth $142,000 after purchasing an additional 4,630 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Aclaris Therapeutics in the 3rd quarter worth about $40,000. HighTower Advisors LLC boosted its holdings in shares of Aclaris Therapeutics by 3.5% in the 3rd quarter. HighTower Advisors LLC now owns 225,190 shares of the biotechnology company’s stock worth $1,184,000 after purchasing an additional 7,666 shares in the last quarter. Finally, MBE Wealth Management LLC bought a new position in shares of Aclaris Therapeutics during the 3rd quarter valued at about $53,000. 98.34% of the stock is owned by institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.
Featured Stories
- Five stocks we like better than Aclaris Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
